The Evolving Landscape of Factor Replacement Therapy – EAHAD
European Association for Haemophilia and Allied Disorders (EAHAD) shared a post on LinkedIn:
“Summer is the perfect time to catch up on the educational content you’ve been meaning to watch and stay up to date with the latest developments in haemophilia care.
One topic that continues to evolve rapidly is factor replacement therapy.
As treatment options expand, choosing the most appropriate factor VIII and factor IX replacement products and understanding how monitoring is changing has become increasingly important for delivering personalised care.
In this recorded session, Jan Astermark, Annette Bowyer and Cedric Hermans (Lon,Edin) examine the latest evidence, discuss the expanding therapeutic landscape, and explore how monitoring is evolving to support more precise, individualised treatment decisions.
What session is next on your summer learning list?”
Other posts about European Association for Haemophilia and Allied Disorders on Hemostasis Today.
-
Nov 17, 2026, 05:30Nathan Connell: Women’s Hematology Summit 2027 to Address Hematologic Health Across the Lifespan
-
Nov 17, 2026, 05:25Mane Kurghinyan: Representing Armenia and HemAI Dynamics at the Falling Walls Lab Global Finale 2026
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound